University of California Davis Health (Pediatric & Adult Site)
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cohen, Stuart
DECREASE SSI, NCT05586776: Decolonization to Reduce After-Surgery Events of Surgical Site Infection

Recruiting
4
2700
US
4% Chlorhexidine Gluconate, 2% Mupirocin, Soap Without Antiseptic Properties (Placebo), Placebo Nasal Ointment
University of California, Irvine, University of California, Davis, University of California, San Francisco, University of Massachusetts, Amherst, Hoag Memorial Hospital Presbyterian
Surgical Site Infection
12/27
12/28
D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed
3
407
Europe, Canada, US, RoW
Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir
Eiger BioPharmaceuticals
Hepatitis Delta Virus
10/22
03/23
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Recruiting
3
274
Europe, US, RoW
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Ansun Biopharma, Inc.
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
08/25
08/25

Download Options